scholarly journals Optical Biosensors for Therapeutic Drug Monitoring

Biosensors ◽  
2019 ◽  
Vol 9 (4) ◽  
pp. 132 ◽  
Author(s):  
Vivian Garzón ◽  
Daniel Pinacho ◽  
Rosa-Helena Bustos ◽  
Gustavo Garzón ◽  
Sandra Bustamante
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Biological Fluids ◽  
Optical Biosensor ◽  
Pharmacokinetic Analysis ◽  
Optical Biosensors ◽  
Therapeutic Drug ◽  
Label Free ◽  
Biological Recognition ◽  
Clinical Interest

Therapeutic drug monitoring (TDM) is a fundamental tool when administering drugs that have a limited dosage or high toxicity, which could endanger the lives of patients. To carry out this monitoring, one can use different biological fluids, including blood, plasma, serum, and urine, among others. The help of specialized methodologies for TDM will allow for the pharmacodynamic and pharmacokinetic analysis of drugs and help adjust the dose before or during their administration. Techniques that are more versatile and label free for the rapid quantification of drugs employ biosensors, devices that consist of one element for biological recognition coupled to a signal transducer. Among biosensors are those of the optical biosensor type, which have been used for the quantification of different molecules of clinical interest, such as antibiotics, anticonvulsants, anti-cancer drugs, and heart failure. This review presents an overview of TDM at the global level considering various aspects and clinical applications. In addition, we review the contributions of optical biosensors to TDM.

Stealth modified bottom up SERS substrates for label-free therapeutic drug monitoring of doxorubicin in blood serum

Talanta ◽  
2020 ◽  
Vol 218 ◽  
pp. 121138 ◽  
Author(s):  
Sandeep Surendra Panikar ◽  
Nehla Banu ◽  
Elia-Reza Escobar ◽  
Gonzalo-Ramírez García ◽  
Jesús Cervantes-Martínez ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Blood Serum ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Label Free ◽  
Bottom Up ◽  
Sers Substrates

Ultrasensitive SERS Substrate for Label-Free Therapeutic-Drug Monitoring of Paclitaxel and Cyclophosphamide in Blood Serum

2018 ◽  
Vol 91 (3) ◽  
pp. 2100-2111 ◽  
Author(s):  
Sandeep Surendra Panikar ◽  
Gonzalo Ramírez-García ◽  
Siraj Sidhik ◽  
Tazara Lopez-Luke ◽  
Claramaria Rodriguez-Gonzalez ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Blood Serum ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Sers Substrate ◽  
Label Free

Individualization of high dose carboplatin based on therapeutic drug monitoring (TDM) for the treatment of testicular germ cell tumors (TICE protocol): Results of a multicenter phase II study.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 4554-4554 ◽  
Author(s):  
Fabienne Thomas ◽  
Sotheara Moeung ◽  
Sophie Broutin ◽  
Jerome Guitton ◽  
Michele Boisdron-Celle ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Germ Cell ◽  
Phase Ii ◽  
Drug Monitoring ◽  
Germ Cell Tumors ◽  
Pharmacokinetic Analysis ◽  
Therapeutic Drug ◽  
High Dose ◽  
Clearance Prediction ◽  
New Equation

4554 Background: We conducted a national phase II multicenter trial that aimed at evaluating the efficacy and tolerance of Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide treatment (TICE) in previously treated germ cell tumors. The particularity of our study (in comparison with the standard protocol [Motzer RJ, et al. J Clin Oncol 2000 Mar; 18(6): 1173-1180.]) is that the carboplatin dose was individualized for each patient according to therapeutic drug monitoring (TDM) in order to reach the target AUC of 24 mg.min/ml over 3 days. Methods: In total, 89 patients were evaluable for pharmacokinetic study. Blood samples were taken on day 1 to determine the carboplatin clearance using a Bayesian approach (NONMEM 7.2) and to adjust the dose on day 3 to reach the target AUC of 24 mg.min/ml over 3 days. On days 2 and 3, samples were taken for retrospective assessment of the actual AUC and the intra- and inter-cycle clearance variability. Secondly, a population pharmacokinetic analysis was also performed on 59 patients using NONMEM to develop a covariate equation for carboplatin clearance prediction adapted for future patients treated with the TICE protocol. The performance of this new equation was then prospectively evaluated on the other 30 patients along with different methods of carboplatin clearance prediction. Results: TDM allowed us to control the carboplatin exposure with a mean actual AUC of 24.5 mg.min/ml (22.2 and 28.0 for 5th and 95thpercentile respectively) per cycle. We observed a modest but significant decrease of carboplatin clearance over cycles (median value of change of -11.8% from cycle 1 to cycle 3, maximum value of -36%). The new covariate equation allows unbiased and more accurate prediction of carboplatin clearance in the prospective validation cohort compared to other equations. Conclusions: Carboplatin TDM allowed the target AUC to be accurately reached and thereby avoid over- or under-exposure. We propose a new equation to predict carboplatin clearance more adapted to these particular patients (young males) that could be used as an alternative if the TDM cannot be organized. Clinical trial information: 2008-005068-14.

Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data

2004 ◽  
Vol 59 (2-3) ◽  
pp. 155-165 ◽  
Author(s):  
Dina Battino ◽  
Danilo Croci ◽  
Daniela Mamoli ◽  
Sara Messina ◽  
Emilio Perucca
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Monitoring Data ◽  
Pharmacokinetic Analysis ◽  
Therapeutic Drug
Sign in / Sign up

Export Citation Format

Share Document